TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02702466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPA Therapy
Description: Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPA Therapy
Description: Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
Study: NCT01441843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Once 1mg \<75kg body weight, 1.5mg 75kg and \>75kg body weight, IV, before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% (Sodium Chloride)
Description: Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
Study: NCT02750189

Intervention type: OTHER
Intervention: Direct cost
Description: Money spent to treat COPD in medical institute based on HIRA

Intervention type: OTHER
Intervention: Direct cost
Description: Money spent to treat COPD in medical institute based on HIRA

Intervention type: OTHER
Intervention: Direct cost
Description: Money spent to treat COPD in medical institute based on HIRA

Intervention type: OTHER
Intervention: Direct cost
Description: Money spent to treat COPD in medical institute based on HIRA

Intervention type: OTHER
Intervention: Indirect cost
Description: extra-expanses excluding hospital fees

Intervention type: OTHER
Intervention: Indirect cost
Description: extra-expanses excluding hospital fees

Intervention type: OTHER
Intervention: Indirect cost
Description: extra-expanses excluding hospital fees

Intervention type: OTHER
Intervention: Indirect cost
Description: extra-expanses excluding hospital fees
Study: NCT04581265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin
Description: Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
Study: NCT05572866

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
Study: NCT04348266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus.
Study: NCT02040649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-sedation
Description: Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control, sedation (propofol, midazolam)
Description: Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
Study: NCT00964496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.

Intervention type: DRUG
Group type: OTHER
Intervention: Iron
Description: Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study: NCT01246427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRN01
Description: 2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Study: NCT03687788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
Study: NCT03564288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: SKI-G-801 is administered as an IV infusion over 10 minutes
Study: NCT04315155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
Study: NCT03255902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting classes
Description: Parenting Classes:The Incredible Years curriculum
Study: NCT00921271

Intervention type: DEVICE
Intervention: Monitoring of StO2
Description: Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
Study: NCT03145740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive F.O.T.T.®
Description: Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unspecific Stimulation of face and mouth
Description: The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
Study: NCT03360435

Intervention type: DIETARY_SUPPLEMENT
Intervention: Patch MD MultiVitamin Plus patch
Description: The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
Study: NCT03091725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Description: A bariatric surgery procedure which will help individuals achieve 16-18% weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very low-calorie diet
Description: Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
Study: NCT00956735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio
Description: 3.0 oz (2 servings) of roasted and salted or unsalted pistachios
Study: NCT02305030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study: NCT03188146

Intervention type: DRUG
Intervention: Ursodeoxycholic Acid
Description: Standard care of PBC patients
Study: NCT02914639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF0166 Topical Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF0166 Topical Ophthalmic Solution
Study: NCT03282058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silastic Stent
Description: The silastic stent is a splint made of silicone.
Study: NCT01936571

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
Study: NCT03439501

Intervention type: DRUG
Group type: OTHER
Intervention: avelumab
Description: * Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle.
Study: NCT00304174

Intervention type: BEHAVIORAL
Intervention: Motivation to eat
Description: Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.

Intervention type: BEHAVIORAL
Intervention: Motivation to eat
Description: Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
Study: NCT03078322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT01900158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex, Gemcitabine and Cisplatin
Description: Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
Study: NCT04122365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Wall Mobilization Program
Description: Soft tissue therapy and joints mobilization

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Routine limbs exercises and education
Study: NCT01295359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground Walking Program
Description: The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
Study: NCT05730296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: 10 rTMS sessions combined with cognitive training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: 10 rTMS sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: 10 sham coils sessions without cognitive training
Study: NCT01726894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Study: NCT03301883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as per the schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs
Description: Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSs
Description: Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
Study: NCT03268785

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative identification method
Description: After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
Study: NCT02414815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic action potential(MAP) catheter
Description: After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
Study: NCT02451085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training with video therapy
Description: training with video therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional exercise
Description: training in conventional way
Study: NCT04555395

Intervention type: OTHER
Intervention: survival rates
Description: survival rates

Intervention type: OTHER
Intervention: survival rates
Description: survival rates

Intervention type: OTHER
Intervention: survival rates
Description: survival rates

Intervention type: OTHER
Intervention: survival rates
Description: survival rates
Study: NCT03573414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: raspberry powder, milled flaxseed and soy milk
Description: * The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~* The participants will provide blood and urine samples
Study: NCT00971802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 20 mg or Placebo, daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 60 mg or Placebo, daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 120 mg or Placebo, daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 185 mg or Placebo, daily for 10 days.
Study: NCT04562454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific diet
Description: use a specific diet in different days with CGM to konw GI of different food in diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific diet
Description: use a specific diet in different days with CGM to konw GI of different food in diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific diet
Description: use a specific diet in different days with CGM to konw GI of different food in diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific diet
Description: use a specific diet in different days with CGM to konw GI of different food in diabetes
Study: NCT03831477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
Study: NCT03309566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, tenofovir disoproxil fumarate and emtricitabine
Description: Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, tenofovir disoproxil fumarate and emtricitabine
Description: Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
Study: NCT03642977

Intervention type: DIAGNOSTIC_TEST
Intervention: Real time PCR and RT-PCR for DNA and RNA viral species
Description: Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
Study: NCT02095470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope
Description: newly developed innovatory device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: traditional laryngoscope
Description: traditional way for intubation
Study: NCT03308344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
Study: NCT02517931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine Ganglion Block
Description: Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
Study: NCT01841879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Program
Description: Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Intervention
Description: Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.